despit
year
extens
research
definit
drug
current
avail
treat
acut
respiratori
distress
syndrom
ard
support
therapi
remain
mainstay
treatment
improv
drug
develop
ard
research
need
deepli
analyz
omic
approach
reevalu
suitabl
therapeut
target
resolv
problem
inadequ
anim
model
develop
strategi
reduc
heterogen
reconsid
new
therapeut
analyt
approach
better
design
clinic
trial
ard
describ
clinic
syndrom
character
enhanc
alveolarcapillari
membran
permeabl
interstiti
alveolar
edema
format
neutrophilsderiv
inflamm
dysfunct
surfact
impair
ga
exchang
respiratori
failur
due
progress
refractori
hypoxemia
accord
berlin
criteria
replac
americaneuropean
consensu
confer
definit
ard
ard
gener
diagnos
follow
criteria
fulfil
sever
hypoxemia
acut
onset
week
bilater
radiograph
abnorm
explain
atelectasi
lack
clinic
heart
failur
echocardiographi
demonstr
disord
caus
heart
failur
ard
classifi
mild
mmhg
pao
fio
mmhg
moder
mmhg
pao
fio
mmhg
sever
pao
fio
mmhg
establish
berlin
criteria
mild
ard
patient
term
acut
lung
injuri
ali
sinc
late
clinic
trial
ard
start
unfortun
appropri
pharmacolog
therapi
ard
manag
exist
support
therapi
lower
tidal
volum
ventil
mlkg
predict
bodi
weight
plateau
airway
pressur
cm
h
prone
posit
neuromuscular
blockad
fluidconserv
therapi
remain
essenti
element
good
outcom
ard
patient
howev
recent
observ
studi
world
reveal
high
incid
mortal
rate
preval
intens
care
unit
icu
mortal
mortal
rate
vari
depend
age
etiolog
lung
injuri
presenc
nonpulmonari
organ
dysfunct
moreov
patient
surviv
ard
high
risk
depress
cognit
declin
persist
skeletalmuscl
weak
posttraumat
stress
disord
henc
new
potenti
approach
need
enhanc
drug
develop
ard
order
improv
qualiti
life
ard
patient
minim
ardsassoci
mortal
review
briefli
discuss
pathophysiolog
genom
ard
target
scrutin
complet
ongo
clinic
trial
target
moreov
also
discuss
perspect
regard
reason
failur
includ
absenc
authent
preclin
data
either
due
poor
represent
human
condit
anim
model
enrol
heterogen
group
patient
clinic
trial
arbitrari
decis
regard
drug
deliveri
durat
therapi
suggest
novel
approach
improv
probabl
success
includ
appropri
use
vitro
assay
screen
new
compound
implement
new
analyt
approach
narrow
subtyp
target
popul
improv
clinic
trial
design
final
summar
therapi
warrant
test
futur
therapeut
strategi
includ
gene
therapi
administr
mesenchym
stem
cell
combin
therapi
target
inflammasom
ubiquitinproteasom
system
characterist
sever
ard
perceiv
assort
involv
pathophysiolog
biomark
depict
tabl
accord
origin
characterist
lung
initi
respons
injuri
refer
exudativeiniti
phase
ard
character
increas
permeabl
rapid
interstiti
alveolar
edema
alveolar
flood
proteinrich
fluid
gradual
refractori
hypoxemia
type
ii
cell
alveolar
epithelium
also
injur
eventu
lead
disrupt
epithelium
integr
attenu
surfact
product
inhibit
epitheli
repair
process
moreov
neutrophil
activ
microthrombi
format
lung
potenti
inflammatori
respons
fibroprolif
phase
driven
proinflammatori
cytokin
character
refractori
hypoxemia
architectur
chang
phase
alveolar
edema
subsid
alveolar
space
fill
neutrophil
macrophag
alveolar
epithelium
repopul
type
ii
cell
final
chronic
inflamm
neovascular
fibroprolif
process
take
place
acknowledg
deposit
extracellular
matrix
repair
process
initi
fibroprolif
phase
ard
essenti
host
surviv
epitheli
integr
reestablish
reabsorpt
alveolar
edema
provision
matrix
restor
alveolar
architectur
function
neutrophilmedi
inflamm
also
revers
probabl
due
apoptosi
final
fibrot
phase
ard
occur
patient
link
prolong
mechan
ventil
increas
mortal
unpredict
consequ
ard
frustrat
pediatr
intensivist
one
two
ard
patient
age
ident
trigger
may
die
other
may
surviv
recent
advanc
genom
suggest
unpredict
consequ
might
due
genet
background
genom
emerg
field
multicent
studi
investig
associ
gene
polymorph
ard
date
numer
genom
studi
highlight
associ
traumaassoci
ali
ppfia
ard
risk
adipoq
sever
mortal
ali
ard
outcom
ard
knowledg
genet
factor
involv
ard
suscept
infanc
studi
larger
patient
popul
differ
ethnic
need
identifi
genet
factor
associ
ard
develop
person
medicin
approach
hundr
random
control
trial
rct
pharmacolog
compound
accomplish
adjuv
therapi
ard
date
avail
therapeut
strategi
intend
earli
recognit
rectif
underli
caus
ard
treatment
ard
difficult
underli
diseas
process
incomplet
understood
therapi
date
develop
larg
target
individu
compon
complex
pathophysiolog
might
lack
great
therapeut
agent
target
portion
perturb
may
effect
drugscompound
studi
previou
trial
outlin
therapeut
highdos
moderatedos
corticosteroid
far
fail
exhibit
efficaci
ard
interestingli
prolong
lowdos
corticosteroid
effect
decreas
icu
mortal
earli
adult
ard
patient
pediatr
regardless
metaanalysi
systemat
review
role
steroid
ard
patient
remain
uncertain
unclear
moreov
phase
ii
pedali
phase
iv
dexaard
rct
ongo
evalu
safeti
efficaci
methylprednisolon
dexamethason
respect
addit
advers
effect
associ
corticosteroid
includ
electrolyt
imbal
gastrointestin
bleed
hyperglycemia
pancreat
fluid
retent
neuromuscular
weak
increas
infect
rate
might
import
limit
factor
therapi
passiv
transfus
antiserum
prepar
mutant
strain
gramneg
bacteria
lack
sugar
moieti
respons
confer
serotyp
specif
show
protect
variou
strain
gramneg
bacteria
lp
prepar
prompt
phase
iii
studi
human
monoclon
antiendotoxin
antibodi
design
neutral
harm
effect
lp
conduct
show
improv
surviv
convincingli
posit
outcom
contrast
show
therapeut
benefit
multicent
rct
treat
septic
shock
sepsisassoci
ard
research
discard
preclin
observ
studi
authent
potenti
role
statin
ard
wherea
clinic
trial
rosuvastatin
sail
simvastatin
fail
show
mortal
benefit
ard
oneyear
followup
rosuvastatin
vs
placebo
sepsisassoci
ard
demonstr
increas
cumul
mortal
survivor
experienc
physic
mental
impair
phase
ii
multicent
studi
recruit
particip
evalu
safeti
doserespons
relationship
ulinastatin
serin
proteas
inhibitor
ard
tabl
antitnfa
therapi
show
promis
outcom
preclin
studi
afelimomab
antitnfa
monoclon
antibodi
improv
surviv
rate
sever
sepsi
common
caus
ard
show
potenti
confus
variabl
metaanalysi
antitnfa
therapi
also
reveal
improv
surviv
sepsi
moreov
etanercept
antitnfa
agent
combin
etanercept
corticosteroid
improv
surviv
children
idiopath
pneumonia
syndrom
ip
ip
acut
noninfecti
lung
disord
associ
high
morbid
mortal
hematopoiet
stem
cell
transplant
hsct
patient
sever
end
spectrum
may
present
hypoxem
respiratori
failur
pulmonari
infiltr
meet
criteria
ard
moreov
prompt
ard
anim
model
studi
earlyphas
clinic
trial
use
antitnfreceptor
monoclon
antibodi
conduct
attenu
pulmonari
inflamm
via
modul
pulmonari
microvascular
endotheli
function
howev
investig
need
neutrophil
andor
neutrophilsderiv
product
demonstr
central
role
pathogenesi
ard
multicent
doubleblind
strive
studi
sivelestat
neutrophil
elastas
inhibitor
show
efficaci
result
broad
spectrum
ali
ard
case
wherea
phase
iii
phase
iv
studi
prolong
use
sivelestat
conduct
japan
demonstr
posit
outcom
moreov
recent
studi
support
therapeut
effect
earli
administr
sivelestat
ard
patient
well
nonrandom
postmarket
henc
therapeut
effect
sivelestat
treat
aliard
yet
inconsist
controversi
tissu
factor
tf
potent
initi
extrins
coagul
cascad
releas
ard
alveolar
epitheli
cell
mediat
procoagul
state
via
fibrin
format
subsequ
result
vascular
injuri
microthrombi
format
complementmedi
activ
platelet
leukocyt
treatment
ard
baboon
model
siteinactiv
fviia
fviiai
attenu
ard
phase
ii
studi
fviiai
human
ard
patient
discontinu
prematur
due
increas
bleed
complic
phase
ii
studi
also
known
recombin
antibodi
bind
tf
tffactor
viii
complex
sepsisinduc
ard
complet
result
await
moreov
nebul
heparin
found
associ
attenu
mechan
ventil
durat
atrisk
ard
patient
trial
nebul
heparin
ongo
henc
trial
need
addit
prehospit
aspirin
therapi
recent
clinic
studi
reveal
signific
effect
aspirin
phase
ii
rct
star
arena
enrol
particip
order
assess
oxygen
index
aspirin
ard
patient
tabl
addit
prompt
anim
studi
activ
protein
c
apc
test
human
model
apc
xigri
therapi
reveal
neg
outcom
sepsi
ard
patient
moreov
intraven
recombin
humanapc
rhapc
amelior
ard
critic
ill
patient
target
factor
endors
mitogen
cytoprotect
effect
lung
epithelium
recent
paradigm
ard
therapeut
strategi
keratinocyt
growth
factor
kgf
stimul
prolifer
type
ii
alveolar
cell
repair
injur
alveoli
previou
data
clinic
relev
human
model
ard
support
potenti
therapeut
role
kgf
palifermin
ard
contrast
recent
phase
ii
clinic
trial
reveal
palifermin
recommend
treat
ard
addit
phase
ii
trial
show
granulocyt
macrophag
colonystimul
factor
gmcsf
pleiotrop
cytokin
chang
ventilatorfre
day
mortal
interestingli
promis
result
phase
inhal
molgramostim
rhgmcsf
motiv
research
conduct
phase
ii
trial
pneumoniaassoci
ard
patient
moreov
two
clinic
trial
includ
conduct
understand
role
vascular
endotheli
growth
factor
ard
stop
due
poor
enrol
lack
fund
earli
ard
immun
activ
lead
intrapulmonari
system
releas
cytokin
alveolar
macrophag
peripher
blood
monocyt
variou
antiinflammatori
approach
perform
deactiv
cell
instanc
vitamin
c
vitamin
exhibit
antiinflammatori
properti
underli
molecular
mechan
uncertain
phase
iiiii
trial
recruit
particip
evalu
effect
highdos
vitamin
c
establish
ard
patient
vitamin
supplement
ard
develop
highrisk
patient
tabl
insulin
exhibit
antiinflammatori
effect
via
inhibit
nuclear
factor
kappa
b
nfjb
phase
ii
trial
insulin
therapi
prevent
ard
complet
result
await
addit
ineffect
date
pharmacolog
strategi
includ
antioxid
nacetylcystein
exogen
surfact
inhal
nitric
oxid
prostaglandin
lisofyllin
agonist
procystein
supplement
nebul
sodium
nitroprussid
calfact
furosemid
consider
disappoint
rct
outcom
kind
strategi
might
adopt
improv
possibl
drug
develop
ard
actual
singl
answer
justifi
question
numer
strategi
warrant
consider
section
provid
perspect
regard
strategi
improv
drug
develop
ard
case
ard
outstand
care
attent
requir
cellbas
assay
instanc
primari
cell
cultur
might
advantag
rather
immort
cell
cultur
likewis
outcom
obtain
human
cell
reliabl
compar
murin
cell
addit
vivo
environ
cell
feedback
proinflammatori
stimuli
thought
distort
local
cellular
humor
factor
reason
vitro
new
advanc
adopt
better
growth
cell
combin
differ
cell
type
order
imit
vivo
environ
tissu
organ
might
facilit
compound
screen
select
develop
promis
candid
uniqu
challeng
ard
model
limit
evalu
appropri
result
clinic
trial
first
young
healthi
anim
mainli
use
preclin
studi
major
ard
patient
old
age
sever
charact
ard
mice
agedepend
oldag
mice
inflammatori
respons
impair
decreas
adapt
immun
lead
worsen
ard
therefor
use
age
anim
rather
young
could
improv
clinic
signific
anim
model
ard
second
rodent
particularli
mice
chronic
coldstress
hous
laboratoryanim
center
suggest
appropri
physiolog
condit
hous
laboratori
mice
might
help
get
better
preclin
find
third
compound
mainli
administ
prior
onset
ard
experiment
setup
clinic
diagnosi
treatment
delay
case
ard
patient
therebi
proper
justif
outcom
compound
test
prior
well
onset
ard
fourth
anim
rat
mice
baboon
surprisingli
less
sensit
toxic
effect
lp
human
obviou
inconsist
lp
sensit
seem
one
key
factor
may
lead
inappropri
inconsist
outcom
fifth
fundament
differ
exhibit
physiolog
anatomi
size
speci
anim
rodent
primat
human
primat
pig
close
relat
human
compar
mice
mani
aspect
immunolog
function
human
pig
alik
instanc
circul
white
blood
cell
human
pig
primarili
polymorphonuclear
leukocyt
mice
interleukin
il
direct
ortholog
pig
mice
moreov
larg
quantiti
produc
murin
macrophag
lp
stimul
wherea
neither
porcin
human
macrophag
counter
lp
way
human
mice
thought
potenti
way
improv
ard
anim
model
human
mice
develop
transplant
human
umbil
cord
blood
hematopoiet
stem
cell
gammairradi
neonat
null
mice
nonobes
diabet
sever
combin
immunodefici
mice
lack
gchain
receptor
develop
human
mice
repres
absolut
lineag
human
cell
macrophag
monocyt
cell
b
cell
natur
killer
cell
plasmacytoid
myeloid
dendrit
cell
exhibit
limit
limit
includ
expens
multifacet
timeconsum
gener
inconsist
adopt
transplant
human
cell
presenc
murin
epitheli
endotheli
cell
respiratori
tract
investig
tri
overcom
current
limit
creat
improv
human
mice
ex
vivo
lung
perfus
evlp
system
potenti
approach
solv
issu
scarciti
human
lung
owe
poor
oxygen
poor
lung
complianc
visibl
lung
injuri
almost
evalu
lung
thought
inappropri
transplant
evlp
ventil
perfus
lung
sever
hour
better
vivo
stimulatori
condit
allow
observ
variou
physiolog
measur
evlp
system
also
implement
preclin
model
appli
endotoxin
bacteria
hypothesistest
ard
therapi
screen
mechan
drug
action
use
pharmacolog
agonist
antagonist
clinic
trial
perform
check
whether
evlp
improv
suitabl
lung
transplant
lungonachip
microdevic
anoth
potenti
therapeut
screen
strategi
creat
clinic
relev
human
diseas
model
system
suitabl
human
cell
line
persist
longterm
cultur
recent
alveolar
epitheli
cell
deriv
lung
cancer
cell
line
use
studi
toxic
effect
drug
pulmonari
edema
lungonachip
microdevic
remark
model
also
evalu
therapeut
effect
coadministr
new
inhibitor
transient
receptor
potenti
vanilloid
suppress
pulmonari
vascular
leakag
method
thought
conveni
drug
screen
evlp
henc
evlp
lungonachip
microdevic
might
help
test
compound
proceed
human
trial
final
genom
edit
endonucleas
cluster
regularli
interspac
short
palindrom
repeat
crispr
crisprassoci
protein
system
revolution
induc
sitespecif
dna
cleavag
insert
specif
point
mutat
human
genom
tissu
thu
far
coronavirusinduc
ard
mous
model
develop
edit
futur
implement
genom
edit
ard
help
polymorph
gene
identif
via
genomewid
associ
studi
provid
variou
genom
evid
pathogenesi
ard
advantag
research
develop
new
drug
treat
ard
differ
genet
background
controversi
issu
clinic
studi
ard
heterogen
group
patient
make
indistinguish
lung
patholog
cryptogen
organ
pneumonia
diffus
alveolar
damag
pulmonari
hemorrhag
allerg
pneumon
variou
preclin
clinic
outcom
reveal
pharmacolog
approach
advantag
patient
detriment
other
due
variat
ard
etiolog
patholog
associ
morbid
henc
signaltonois
ratio
might
improv
tighten
enrol
criteria
via
recogn
suitabl
subgroup
reduc
heterogen
trial
neuromuscular
blockad
prone
posit
illustr
worth
reduc
heterogen
sever
ard
exclud
patient
major
comorbid
advanc
lung
liver
diseas
malign
dementia
import
approach
minim
heterogen
clinic
studi
moreov
presenc
vasopressindepend
shock
higher
pulmonari
dead
space
fraction
respons
peep
posit
endexpiratori
pressur
computer
tomographi
ct
scan
might
help
minim
heterogen
clinic
trial
identif
subphenotyp
patient
meet
ard
criteria
anoth
effect
approach
reduc
heterogen
ard
subdivid
trauma
vs
sepsi
basi
clinic
risk
factor
diffus
vs
focal
account
radiograph
chang
accumul
evid
propos
differ
clinic
outcom
treatment
respons
direct
indirect
lung
injuri
caus
clinic
biolog
differ
measur
plasma
level
lung
injuri
biomark
anoth
complex
approach
identifi
ard
patient
hyperinflammatori
subphenotyp
higher
mortal
exampl
discret
ard
subphenotyp
recogn
basi
biomark
profil
respons
fluid
manag
strategi
meyer
calfe
discuss
implement
approach
detail
novel
analyt
approach
need
exploit
insight
gain
integr
composit
molecular
clinic
data
drug
develop
measur
biomark
regressionbas
method
common
approach
led
understand
advanc
biolog
ard
well
analyz
genet
polymorph
rna
dna
sequenc
proteom
metabolom
import
limit
approach
facilit
analys
heterogen
within
ard
henc
altern
analyt
approach
need
past
sever
decad
research
quantifi
biolog
complex
develop
novel
statist
method
examin
heterogen
novel
statist
method
case
asthma
result
signific
advanc
understand
diseas
endotyp
differenti
respons
therapi
current
statist
method
similar
goal
extens
focus
translat
studi
seriou
ill
clusterbas
method
includ
differ
analyt
techniqu
identifi
cluster
observ
ident
characterist
instanc
jmean
cluster
hierarch
cluster
method
normal
use
identifi
cluster
patient
similar
genom
data
accumul
cluster
data
evalu
differ
clinic
phenotyp
clinic
outcom
desir
variabl
exampl
includ
identif
subclass
pediatr
septic
shock
identif
endotyp
asthma
studi
cluster
ard
exhibit
advantag
role
reduc
heterogen
perform
baselin
characterist
without
consid
result
classif
regress
tree
analysisclassif
tree
similar
cluster
analysi
anoth
advanc
analyt
approach
approach
identifi
unexpect
cutpoint
data
gener
branch
treelik
structur
given
variabl
end
variou
termin
node
frequent
acclaim
characterist
outcom
treebas
model
use
recogn
prognost
clinic
deterior
hospit
inpati
improv
prognost
stratif
basi
plasma
biomark
septic
shock
patient
identifi
clinic
featur
link
poor
outcom
ard
treelik
structur
establish
basi
relationship
deliber
variabl
explicit
clinic
outcom
treebas
model
also
need
potenti
arbitrari
decis
concern
number
branch
termin
node
clusterbas
model
method
resampl
crossvalid
develop
recogn
decis
latent
class
analysi
anoth
approach
identifi
unobserv
subgroup
socal
latent
within
larger
group
help
research
estim
movement
subgroup
time
extens
use
psychiatr
research
studi
asthma
endotyp
two
discret
ard
subphenotyp
recogn
basi
biomark
profil
respons
randomli
assign
peep
fluidconserv
manag
strategi
latent
class
analysi
latent
class
analysi
also
identifi
subgroup
ard
major
trauma
mainli
distinguish
plasma
biomark
express
clinic
characterist
compar
larg
dataset
n
need
fit
model
drawback
futur
therapeut
strategi
therapi
warrant
test
therapeut
agent
lowrisk
profil
use
indic
warrant
test
ard
instanc
macrolid
particularli
azithromycin
warrant
evalu
decreas
mortal
improv
outcom
aliard
patient
note
paracetamol
specif
hemoprotein
reduct
decreas
capac
oxid
cellfre
hemoglobin
drive
oxidantmedi
tissu
injuri
lipid
peroxid
pilot
studi
demonstr
enter
administr
paracetamol
g
everi
h
day
sever
sepsi
common
caus
ard
patient
exhibit
harmless
encourag
effect
biomark
lipid
peroxid
acut
renal
injuri
given
larger
trial
paracetamol
need
due
wellrecogn
safeti
profil
low
cost
widespread
avail
adenosin
product
exhibit
protect
role
ard
phase
iii
studi
ard
reveal
intraven
administr
recombin
human
interferonb
ifnb
also
known
traumakin
strikingli
reduc
mortal
synthesi
stimul
ifnb
lung
endotheli
cell
phase
iii
studi
interest
current
recruit
particip
tabl
henc
larger
therapeut
trial
ifnb
warrant
addit
prompt
preclin
output
human
trial
involv
monoclon
antibodi
start
later
termin
due
poor
patient
recruit
expect
investig
futur
adrenomedullin
vasoact
peptid
hormon
reduc
pulmonari
vascular
permeabl
lung
injuri
rodent
model
european
medicin
agenc
ema
recommend
orphan
drug
ard
treatment
ema
clinic
trial
therapi
await
interestingli
anim
studi
suggest
angiotensinconvert
enzym
ace
damag
protect
ard
human
data
somewhat
contradictori
due
genet
phenotyp
propos
protect
effect
therapi
select
popul
human
phase
iia
clinic
trial
recombin
human
earli
ard
patient
complet
result
await
howev
therapi
warrant
test
ard
sepsi
quick
discharg
complement
peptid
anaphylatoxin
dysregul
coagul
occur
due
immun
activ
target
andor
limit
due
inher
redund
biolog
effect
complement
peptid
lack
avail
therapeut
nevertheless
preclin
model
reveal
complement
cascad
effici
restrict
protein
also
known
inhibitor
constitut
releas
proteas
inhibitor
belong
serpin
superfamili
multicent
phase
ii
trial
demonstr
purifi
human
substanti
attenu
mortal
absolut
reduct
even
improv
qualiti
life
sepsisinduc
ard
patient
fascin
outcom
yet
use
larger
phase
iiiii
trial
ubiquitin
small
regulatori
molecul
found
eukaryot
tissu
ubiquitin
posttransl
modif
process
take
place
attach
ubiquitin
substrat
protein
serv
signal
ubiquitin
degrad
via
lysosom
proteasom
ard
character
elev
express
ubiquitin
ligas
compon
within
alveolar
epitheli
type
ii
cell
releas
ubiquitinproteasom
compon
bronchoalveolar
lavag
fluid
activ
ubiquitinproteasom
system
target
proteasom
induc
antiinflammatori
effect
us
food
drug
administr
recent
regist
proteasom
inhibitor
includ
carfilzomib
bortezomib
multipl
myeloma
treatment
ubiquitinproteasom
degrad
hypoxiainduc
target
pharmacolog
stabil
attenu
ard
sever
preclin
model
propos
protect
effect
ard
moreov
sever
ard
septic
shock
viral
pneumonia
cytokinedriven
system
inflamm
effect
attenu
preclin
model
target
protein
emphas
potenti
therapi
ard
via
target
ubiquitinproteasom
system
inflammasom
larg
multiprotein
complex
made
three
constitu
includ
nucleotidebind
domain
leucinerichcontain
famili
pyrin
asc
apoptosisassoci
specklik
protein
hypox
cellular
injuri
poreform
toxin
activ
inflammasom
upon
activ
inflammasom
cleav
respect
inflammasomeregul
cytokin
relat
ard
develop
numer
approach
perform
inhibit
upstream
signal
inflammasom
target
attenu
discharg
rat
endotoxemia
inhibit
downstream
pathway
order
block
inflammasom
activ
inflammasom
activ
also
limit
therapi
new
chemic
entiti
directli
target
inflammasom
nlr
yet
miss
canakinumab
monoclon
ab
approv
treat
cryopyrinassoci
period
syndrom
genet
diseas
caus
autosomaldomin
mutat
gene
rilonacept
also
known
trap
ili
inhibitor
anakinra
receptor
antagonist
regist
treat
cryopyrinassoci
period
syndrom
rheumatoid
arthriti
respect
nevertheless
pretend
role
agent
yet
properli
evalu
clinic
set
ard
phase
iv
studi
assess
role
corticosteroid
mediat
ard
via
inflammasom
signal
pathway
still
recruit
particip
treat
ard
via
target
singl
pathogen
pathway
might
defici
complex
cascad
pathogen
event
acut
injuri
alveolarcapillari
membran
activ
innat
adapt
immun
cell
alveolar
edema
clearanc
involv
pathogenesi
ard
instanc
therapi
could
effect
treat
preliminari
lung
injuri
might
suffici
effect
establish
lung
injuri
contrast
therapi
could
improv
resolut
phase
might
ineffect
case
sever
disrupt
alveolarcapillari
membran
henc
theoret
combin
therapi
acut
injuryreduc
agent
resolut
phaseenhanc
agent
might
effect
alon
therapi
instanc
combin
formoterol
aerosol
corticosteroid
budesonid
improv
oxygen
atrisk
ard
patient
secondari
outcom
seven
patient
placebo
group
develop
ard
vs
patient
treat
group
aim
therapi
reduc
lung
inflamm
enhanc
alveolar
fluid
clearanc
henc
studi
show
combin
therapi
might
effect
therapi
either
agent
alon
moreov
fourarm
trial
includ
inhal
placebo
inhal
budesonid
inhal
formoterol
combin
inhal
formoterol
budesonid
feasibl
would
help
stem
cellbas
therapi
ard
emerg
futur
pharmacolog
therapi
numer
mechan
support
assum
role
stem
cell
lung
protect
first
stem
cell
secret
paracrinesolubl
factor
includ
receptor
antagonist
prostaglandin
antimicrobi
peptid
keratinocyt
growth
factor
directli
interact
injur
cell
henc
promot
tissu
repair
alveolar
edema
clearanc
resolut
inflamm
second
stem
cell
potenti
differenti
lung
endotheli
alveolar
epitheli
cell
directli
reconstitut
capillaryalveolar
barrier
cellular
injuri
interestingli
bone
marrowderiv
mesenchym
stem
cell
msc
intens
clinic
investig
alter
local
system
inflammatori
respons
differenti
cell
reconstitut
vascular
epitheli
surfac
provid
protect
lpsinduc
lung
injuri
exogen
administr
msc
demonstr
posit
outcom
ard
anim
model
instanc
infus
cryopreserv
human
msc
repair
ventilationinduc
lung
injuri
attenu
alveolar
permeabl
restor
alveolar
fluid
clearanc
minim
inflamm
injur
human
lung
condit
media
obtain
msc
might
therapeut
futur
obviat
need
cell
cryopreserv
phase
trial
demonstr
infus
bone
marrowor
allogen
adiposederiv
msc
safe
might
attenu
circul
marker
alveolar
epitheli
injuri
moder
sever
ard
patient
clinic
studi
recruit
particip
evalu
phase
iii
stem
cellbas
therapi
ard
depict
tabl
gene
therapi
promis
approach
use
limit
anim
model
instanc
adenoassoci
viru
vector
contain
ecsod
transgen
reduc
sever
ard
similarli
nanoparticl
receptor
significantli
attenu
ard
sever
establish
ard
mice
model
interestingli
among
variou
identifi
ard
gene
alveolar
fluid
clearanc
gene
therapeut
focus
ard
mainli
character
abnorm
accumul
alveolar
fluid
alveolar
space
interstitium
therebi
na
k
atpas
regul
fluid
transport
across
cell
membran
potenti
preclin
target
ard
model
gene
therapi
na
k
atpas
improv
develop
lung
injuri
via
improv
alveolar
fluid
clearanc
similarli
gene
therapi
k
atpas
alon
combin
epitheli
sodium
channel
enac
upregul
tight
junction
treat
lpsinduc
ard
addit
clinic
investig
reveal
aquaporin
aqp
act
candid
gene
lung
injuri
sepsi
regul
pulmonari
vascular
permeabl
genet
studi
need
link
polymorph
select
gene
ard
take
togeth
ard
gain
statu
bermuda
triangl
field
drug
develop
therebi
studi
new
development
strategi
combin
increas
knowledg
relev
area
genom
immunolog
appropri
anim
model
apposit
clinicaltri
design
prognost
predict
enrich
strategi
reduc
heterogen
implement
new
analyt
pharmacolog
approach
would
facilit
research
develop
new
drug
ard
